What changed in this filing

/stocks — the workspaceLOADING

Item 1. Legal Proceedings

2020-08-07 compared with 2020-05-14 · 27 added, 30 removed, 8 unchanged (88% of the section changed)

LEGAL PROCEEDINGS

From time to time, we are subject to ordinary

routine litigation incidental to our normal business operations.

We are not currently a party to, and our property is not subject

to, any material legal proceedings, except as set forth below.

On October 25, 2017, Genexosome entered

into and closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome,

pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a

cash payment in the amount of $450,000 of which $100,000 is still owed.

Further, on October 25, 2017, Genexosome entered into

and closed an Asset Purchase Agreement with Dr.

Zhou, pursuant to which we acquired all assets, including all intellectual property

and the exosome separation system, held by Dr.

Zhou pertaining to the business of researching, developing and commercializing

exosome technologies.

time to time, we are subject to ordinary routine litigation incidental to our normal business operations.

We are not currently

a party to, and our property is not subject to, any material legal proceedings, except as set forth below.

October 25, 2017, Genexosome entered into and closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD,

the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities

of Beijing Genexosome in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed.

on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr.

Zhou, pursuant to which the Company

acquired all assets, including all intellectual property and exosome separation systems, held by Dr.

Zhou pertaining to the business

of researching, developing and commercializing exosome technologies.

In consideration of the assets, Genexosome paid Dr.

Zhou $876,087 in cash, transferred 500,000 shares of

common stock of us to Dr.

$876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr.

Zhou and issued Dr.

Zhou 400 shares of common stock of Genexosome.

Further, we had not been

able to realize the financial projections provided by Dr.

Zhou for the sale of the separation systems which were provided to us

at the time of the acquisition and we have decided to impair the intangible asset associated with this acquisition to zero.

Zhou 400 shares of common

stock of Genexosome.

Further, The Company had not been able to realize the financial projections provided by Dr.

at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero.

Zhou was terminated as Co-CEO of Genexosome on August 14, 2019.

2 unchanged sentences

for the Southern District of Ohio Eastern Division against Dr.

Zhou, Li Chen, us and Genexosome with various claims against us

and Genexosome including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and violation

of Ohio Uniform Trade Secrets Act.

Research Institute is seeking monetary damages, injunctive relief, exemplary damages,

injunctive relief and other equitable relief.

Zhou, Li Chen, the Company and Genexosome with various claims against

the Company and Genexosome including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and

violation of Ohio Uniform Trade Secrets Act.

Research Institute is seeking monetary damages, injunctive relief, exemplary

damages, injunctive relief and other equitable relief.

The case number is 2:19-cv-4574.

We intend to vigorously defend against this

action and pursue all available legal remedies.

While there can be no assurances, we believe it has substantial

legal and factual defenses to the Research Institute’s claims.

The Company intends to vigorously defend

against this action and pursue all available legal remedies.

The civil case against Avalon is stayed pending resolution

of the criminal proceedings against Dr.

Zhou and Li Chen, and while there can be no assurances, the Company believes it has

substantial legal and factual defenses to the Research Institute’s claims.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Legal Proceedings